Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jiao-Zhi Cai"'
Autor:
Dan-Ni Wang1 42068691@qq.com, Li-Fang Lei2, Jiao-Zhi Cai3, Fu-Li Zhang1, Hai-Xu Li1, Hong Ye1
Publikováno v:
Clinical Journal of Oncology Nursing. Oct2024, Vol. 28 Issue 5, pE16-E26. 11p.
Autor:
Shun-qin, Long, Xiao-xuan, Zhang, Xiao-bing, Yang, Yu-shu, Zhou, Wen-feng, He, Gui-ya, Liao, Yu-shu, Ouyang, Qiu-ping, Li, Jin-peng, Huang, Hong, Deng, Zong-qi, Pan, Shu-jing, Xiao, Jiao-zhi, Cai, Wan-yin, Wu
Publikováno v:
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 36(2)
To evaluate the clinical efficacy of Jianpi Liqi Yiliu Formula (JLYF) combined with cytokine-induced killer (CIK) cells for treating patients with advanced hepatocellular carcinoma (HCC).Between January 2011 and January 2014, 60 advanced HCC patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc683e6afb0e783a5e42fc6810abff3b
https://pubmed.ncbi.nlm.nih.gov/27078990
https://pubmed.ncbi.nlm.nih.gov/27078990
Autor:
Zong-Qi Pan, Jiao-zhi Cai, Shujing Xiao, Wen-feng He, WanYin Wu, Hong Deng, Gui-ya Liao, Shunqin Long, Xiao-bing Yang, Yu-shu Zhou, Qiu-Ping Li
Publikováno v:
Trials
Background Patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. Chinese herbal medicine (CHM) has been us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f930fa21928015dd396fd0bd66ddeccb
https://doi.org/10.1186/s13063-015-0685-2
https://doi.org/10.1186/s13063-015-0685-2
Autor:
Xiao-Bing, Yang, Shun-Qin, Long, Wan-Yin, Wu, Hong, Deng, Zong-Qi, Pan, Wen-Feng, He, Yu-Shu, Zhou, Gui-Ya, Liao, Yu-Shu, Ouyang, Qiu-Ping, Li, Li, Huang, Xue-Jun, Hu, Shu-Jing, Xiao, Jiao-Zhi, Cai
Publikováno v:
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 33(7)
To explore the distribution of Chinese medicine (CM) syndrome types in primary liver cancer (PLC) and their differences of the survival time.From May 2007 to March 2009, recruited were 151 PLC inpatients at Department of Tumor, Guangdong Provincial H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b24ab118e83bf7a94328938674097171
https://pubmed.ncbi.nlm.nih.gov/24063211
https://pubmed.ncbi.nlm.nih.gov/24063211
Autor:
Xiao-Bing Yang, Wan-yin Wu, Shun-qin Long, Hong Deng, Zong-Qi Pan, Wen-Feng He, Yu-Shu Zhou, Gui-Ya Liao, Qiu-Ping Li, Shu-Jing Xiao, Jiao-Zhi Cai
Publikováno v:
Trials; 2015, Vol. 16 Issue 1, p1-6, 6p, 1 Diagram